You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Prostate cancer discovery opens door to more tailored treatments
- 2. Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis
- 3. Dual roles of methylglyoxal in cancer
- 4. Prostate cancer, race and the need for tests | Letters
- 5. LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
- 6. Halozyme sues Merck; FDA blames cuts for Vanda delay
- 7. Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
- 8. Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
- 9. Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML
- 10. Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
Last updated at 15:39 GMT
Hot News Makers
Health/Pharma Companies
-
30563.68
-
4915.10
-
4022.35
-
2337.88
-
1006.45
-
876.19
-
696.93
-
597.19
-
426.25
-
371.33
Drugs, Treatments, Trials
-
78227.65
-
8787.67
-
5242.16
-
2936.86
-
1890.77
-
1832.57
-
945.54
-
527.83
-
509.14
-
485.73
Last updated at 15:10 GMT
